Molecular Biology Reports

, Volume 39, Issue 2, pp 937–943 | Cite as

Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome

  • Dor Mohammad Kordi-Tamandani
  • Mohammad Hashemi
  • Nooshin Sharifi
  • Mahmoud Ali Kaykhaei
  • Adam Torkamanzehi


Paraoxonase-1 (PON1), a high-density lipoprotein (HDL) associated enzyme, is involved in the metabolism and detoxification of insecticides and pesticides. Three polymorphisms within the PON1 gene affect the enzyme activity. Two of these (L55M and Q192R) are located at the coding region and the third (–107C/T) is in promoter region. We performed a case–control study in order to elucidate the possible contribution of variability within PON1 at three mentioned positions to the risk of MS in a South-East Iranian population. DNA was isolated from peripheral blood of patients (N = 119) with MS and healthy controls (N = 201). Allelic polymorphisms at positions Q192R, L55M and –107C/T in the PON1 gene were studied by Amplification Refractory Mutation System (ARMS)-PCR. It was observed that genotypes RR and QR + RR of Q192R locus significantly increased the risk of MS (OR = 2; 95% CI: 1.17–3.40, P = 0.0001 and OR = 1.62; 95% CI: 1.0–2.63; P = 0.05, respectively). The risk in patients with MM and LM + MM genotypes at the L55M locus was marginal (OR = 1.33; 95% CI: 0.68–1.85; P = 0.34 and OR = 1.12; 95% CI: 0.68–1.85; P = 0.73 respectively). The CC genotype at –107C/T locus also increased the risk of metabolic syndrome, but was not significant. This association was somewhat stronger when combined genotypes at Q192R and L55M loci were analyzed (OR = 3.30; 95% CI: 1.34–8.24; P = 0.007). Our results, in this first study, provide evidence for association of PON1 gene polymorphisms with the risk for metabolic syndrome.


Paraoxonase-1 (PON1) Metabolic syndrome Polymorphism 



The authors thank the University of Sistan and Baluchestan, and Zahedan University of Medical sciences, Zahedan, Iran, for financially supporting this project through grants to DMKT, AT, MH and KM.


  1. 1.
    Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation 111:3465–3472PubMedGoogle Scholar
  2. 2.
    Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation 108:414–419PubMedGoogle Scholar
  3. 3.
    Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMedGoogle Scholar
  4. 4.
    Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMedGoogle Scholar
  5. 5.
    Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A (2007) Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 117:204–210PubMedGoogle Scholar
  6. 6.
    Rutter MK, Meigs JB, Sullivan LM, D’Agostino R B Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation 110:380–385PubMedGoogle Scholar
  7. 7.
    Lteif AA, Han K, Mather KJ (2005) Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112:32–38PubMedGoogle Scholar
  8. 8.
    Pollex RL, Al-Shali KZ, House AA, Spence JD, Fenster A, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Hegele RA (2006) Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovasc Ultrason 4:28Google Scholar
  9. 9.
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMedGoogle Scholar
  10. 10.
    Lee J, Heng D, Ma S, Chew S-K, Hughes K, Tai ES (2008) The metabolic syndrome and mortality: the Singapore cardiovascular cohort study. Clin Endocrinol Oxf 69:225–230PubMedGoogle Scholar
  11. 11.
    Ma W-Y, Li H-Y, Hung CS, Lin M-S, Chiu F-C, Lin C-H, Shih S-R, Chuang L-M, Wei J-N (2009) Metabolic syndrome defined by IDF and AHA/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO. Diabetes Res Clin Pract 85:335–341PubMedGoogle Scholar
  12. 12.
    Wallenfeldt K, Hulthe J, Fagerberg B (2005) The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med 258:28–37PubMedGoogle Scholar
  13. 13.
    Lu B, Yang Y, Song X, Dong X, Zhang Z, Zhou L, Li Y, Zhao N, Zhu X, Hu R (2006) An evaluation of the international diabetes federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus. Metabolism 55:1088–1096PubMedGoogle Scholar
  14. 14.
    Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, Williams K, Gomez-Gerique JA, Stern MP, Haffner SM (2003) Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 11:1480–1487PubMedGoogle Scholar
  15. 15.
    Raymond SU, Leeder S, Greenberg HM (2006) Obesity and cardiovascular disease in developing countries: a growing problem and an economic threat. Curr Opin Clin Nutr Metab Care 9:111–116PubMedGoogle Scholar
  16. 16.
    Prentice AM (2006) The emerging epidemic of obesity in developing countries. Int J Epidemiol 35:93–99PubMedGoogle Scholar
  17. 17.
    Azizi F, Azadbakht L, Mirmiran P (2005) Trends in overweight, obesity and central fat accumulation among Tehranian adults between 1998–1999 and 2001–2002: Tehran lipid and glucose study. Ann Nutr Metab 49:3–8PubMedGoogle Scholar
  18. 18.
    Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265:2037–2048PubMedGoogle Scholar
  19. 19.
    Schork NJ (1997) Genetically complex cardiovascular traits. Origins, problems, and potential solutions. Hypertension 29:145–149PubMedGoogle Scholar
  20. 20.
    Hegele RA (1997) The genetic basis of atherosclerosis. Int J Clin Lab Res 27:2–13PubMedGoogle Scholar
  21. 21.
    Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498–507PubMedGoogle Scholar
  22. 22.
    Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–1684PubMedGoogle Scholar
  23. 23.
    Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154PubMedGoogle Scholar
  24. 24.
    Zhang Y, Zheng F, Du H, Krepinsky JC, Segbo JAG, Zhou X (2006) Detecting the polymorphisms of paraoxonase (PON) cluster in Chinese Han population based on a rapid method. Clin Chim Acta 365:98–103PubMedGoogle Scholar
  25. 25.
    Tomas M, Latorre G, Senti M, Marrugat J (2004) The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 57:557–569PubMedGoogle Scholar
  26. 26.
    Flekac M, Skrha J, Zidkova K, Lacinova Z, Hilgertova J (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 57:717–726PubMedGoogle Scholar
  27. 27.
    Costa LG, Vitalone A, Cole TB, Furlong CE (2005) Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541–550PubMedGoogle Scholar
  28. 28.
    Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516–521PubMedGoogle Scholar
  29. 29.
    Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480PubMedGoogle Scholar
  30. 30.
    Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST (2005) The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38:153–163PubMedGoogle Scholar
  31. 31.
    Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295–298PubMedGoogle Scholar
  32. 32.
    Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469–480PubMedGoogle Scholar
  33. 33.
    Hashemi M, Kordi-Tamandani DM, Sharifi N, Moazeni-Roodi A, Kaykhaei MA, Narouie B, Torkmanzehi A (2011) Paraoxonase and Arylesterase activities in metabolic syndrome in Zahedan, southeast Iran. Eur J Endocrinol 164(2):219–222 Google Scholar
  34. 34.
    Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503–2516PubMedGoogle Scholar
  35. 35.
    Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, Ghavami S (2010) Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 9:333–339PubMedGoogle Scholar
  36. 36.
    Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, Bardestani GR, Zakeri Z, Kordi-Tamandani DM, Ghavami S (2010) The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 9:1735–1741PubMedGoogle Scholar
  37. 37.
    Gupta N, Gill K, Singh S (2009) Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 130:361–368PubMedGoogle Scholar
  38. 38.
    Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73–76PubMedGoogle Scholar
  39. 39.
    Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123–134PubMedGoogle Scholar
  40. 40.
    Ergen A, Kilicoglu O, Ozger H, Agachan B, Isbir T (2010) Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma. Mol Biol Rep. doi: 10.1007/s11033-010-0538-8
  41. 41.
    Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pourmotabbed T, Shakiba E, Kiani A, Aminian M, Alibakhshi R, Bartels C (2011) Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep. doi: 10.1007/s11033-011-0696-3
  42. 42.
    Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276:24473–24481Google Scholar
  43. 43.
    Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435–442PubMedGoogle Scholar
  44. 44.
    Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259–264PubMedGoogle Scholar
  45. 45.
    Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197–203PubMedGoogle Scholar
  46. 46.
    Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923–1929PubMedGoogle Scholar
  47. 47.
    Pola R, Gaetani E, Flex A, Gerardino L, Aloi F, Flore R, Serricchio M, Pola P, Bernabei R (2003) Lack of association between Alzheimer’s disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Dement Geriatr Cogn Disord 15:88–91PubMedGoogle Scholar
  48. 48.
    Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM (2003) Different pattern of association of paraoxonase Gln192–>Arg polymorphism with sporadic late-onset Alzheimer’s disease and coronary artery disease. Neurosci Lett 339:17–20PubMedGoogle Scholar
  49. 49.
    Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, Mizusawa H (1999) No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer’s disease. Neurology 53:1146–1148PubMedGoogle Scholar
  50. 50.
    Helbecque N, Cottel D, Codron V, Berr C, Amouyel P (2004) Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett 358:41–44PubMedGoogle Scholar
  51. 51.
    Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, Reddy KS, Prabhakaran D (2010) Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction and association with oxidized low density lipoprotein. Indian J Med Res 131:522–529PubMedGoogle Scholar
  52. 52.
    Ozturk O, Kagnici OF, Ozturk T, Durak H, Tuzuner BM, Kisakesen HI, Cakalir C, Isbir T (2009) 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res 29:4041–4046PubMedGoogle Scholar
  53. 53.
    Paragh G, Seres I, Harangi M, Pocsai Z, Asztalos L, Locsey L, Szeles G, Kardos L, Varga E, Karpati I, Adany R (2009) Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease. Nephron Clin Pract 113:c46–c53PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Dor Mohammad Kordi-Tamandani
    • 1
  • Mohammad Hashemi
    • 2
  • Nooshin Sharifi
    • 1
  • Mahmoud Ali Kaykhaei
    • 3
  • Adam Torkamanzehi
    • 1
    • 4
  1. 1.Genetics and Biotechnology Research InstituteUniversity of Sistan and BaluchestanZahedanIran
  2. 2.Department of Clinical Biochemistry, School of MedicineZahedan University of Medical SciencesZahedanIran
  3. 3.Department of Internal MedicineZahedan University of Medical SciencesZahedanIran
  4. 4.Department of BiologyUniversity of Sistan and BaluchestanZahedanIran

Personalised recommendations